Skip Nav Destination
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets
Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation
Issue Archive
Table of Contents
INSIDE BLOOD COMMENTARIES
PLENARY PAPER
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Clinical Trials & Observations
Michael Crump,Sattva S. Neelapu,Umar Farooq,Eric Van Den Neste,John Kuruvilla,Jason Westin,Brian K. Link,Annette Hay,James R. Cerhan,Liting Zhu,Sami Boussetta,Lei Feng,Matthew J. Maurer,Lynn Navale,Jeff Wiezorek,William Y. Go,Christian Gisselbrecht
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets
CME
Alyssa Bouska,Chengfeng Bi,Waseem Lone,Weiwei Zhang,Ambreen Kedwaii,Tayla Heavican,Cynthia M. Lachel,Jiayu Yu,Roberto Ferro,Nanees Eldorghamy,Timothy C. Greiner,Julie Vose,Dennis D. Weisenburger,Randy D. Gascoyne,Andreas Rosenwald,German Ott,Elias Campo,Lisa M. Rimsza,Elaine S. Jaffe,Rita M. Braziel,Reiner Siebert,Rodney R. Miles,Sandeep Dave,Anupama Reddy,Jan Delabie,Louis M. Staudt,Joo Y. Song,Timothy W. McKeithan,Kai Fu,Michael Green,Wing C. Chan,Javeed Iqbal
Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
Clinical Trials & Observations
Marina Lafage-Pochitaloff,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Laurence Baranger,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Mathilde Hunault,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Wendy Cuccuini,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Christine Lefebvre,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Audrey Bidet,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Isabelle Tigaud,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Virginie Eclache,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Eric Delabesse,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Chrystèle Bilhou-Nabéra,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Christine Terré,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Elise Chapiro,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Nathalie Gachard,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Marie-Joelle Mozziconacci,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Geneviève Ameye,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Sarah Porter,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Nathalie Grardel,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Marie C. Béné,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Yves Chalandon,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Carlos Graux,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Françoise Huguet,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Véronique Lhéritier,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Norbert Ifrah,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Hervé Dombret,on behalf of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
RED CELLS, IRON, AND ERYTHROPOIESIS
Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis
Edyta Glogowska,Eve R. Schneider,Yelena Maksimova,Vincent P. Schulz,Kimberly Lezon-Geyda,John Wu,Kottayam Radhakrishnan,Siobán B. Keel,Donald Mahoney,Alison M. Freidmann,Rachel A. Altura,Elena O. Gracheva,Sviatoslav N. Bagriantsev,Theodosia A. Kalfa,Patrick G. Gallagher
TRANSPLANTATION
Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation
Clinical Trials & Observations
Stefan O. Ciurea,Jolie R. Schafer,Roland Bassett,Cecele J. Denman,Kai Cao,Dana Willis,Gabriela Rondon,Julianne Chen,Doris Soebbing,Indreshpal Kaur,Alison Gulbis,Sairah Ahmed,Katayoun Rezvani,Elizabeth J. Shpall,Dean A. Lee,Richard E. Champlin
BLOOD WORK
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
Various mechanisms of PIEZO1 dysfunction lead to the phenotype of hereditary xerocytosis (HX), including altered membrane protein trafficking. The image shows intracellular retention of HX-associated mutant R2088G PIEZO1 protein in the endoplasmic reticulum (yellow). See the article by Glogowska et al on page 1845.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals